摘要
白血病干细胞(LSC)是急性骨髓性白血病(AML)治疗失败和复发的原因。因此,新LSC靶向治疗策略的开发具有提高AML治疗效果的重大临床重要性。在临床前研究中,组蛋白脱乙酰酶(HDAC)抑制剂表现出了强力且特异的抗癌干细胞活性。西达本胺,一种新苯甲酰胺型选择性HDAC抑制剂,已被报道在相对成熟的起源群体中能诱导G1期阻滞和细胞凋亡,然而它对原始LSC的作用未被阐明。在该研究中,我们证明西达本胺以具有浓度和时间依赖性的方式特异地诱导LSC样细胞和主要AML CD34+细胞的凋亡。我们进一步的分子机制研究揭示了西达本胺通过活化活性氧(ROS)诱导LSC死亡。它通过调节线粒体膜电位,调节B淋巴细胞瘤-2基因(BLC2)家族中的抗凋亡及促凋亡蛋白,激活胱天蛋白酶3(caspase-3)等方式导致DNA聚合酶(PARP)降解。同时,西达本胺活化CD40并调节它的下游信号通路JNK和NFκB。该研究的结果表明西达本胺可能是治疗AML的新LSC靶向剂。
关键词: 急性骨髓性白血病,CD40,组蛋白脱乙酰酶抑制剂,白血病干细胞,线粒体,活性氧
图形摘要
Current Cancer Drug Targets
Title:A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor
Volume: 15 Issue: 6
Author(s): Yin Li, Kai Chen, Yong Zhou, Yiren Xiao, Manman Deng, Zhiwu Jiang, Wei Ye, Xiangmeng Wang and Xinru Wei, Jie Li, Jiabao Liang, Zhongxin Zheng, Yao Yao, Weiguang Wang, Peng Li and Bing Xu
Affiliation:
关键词: 急性骨髓性白血病,CD40,组蛋白脱乙酰酶抑制剂,白血病干细胞,线粒体,活性氧
摘要: Leukemia stem cells (LSCs) are responsible for treatment failure and relapse in acute myeloid leukemia (AML). Therefore, development of novel LSCs-targeting therapeutic strategies is of crucial clinical importance to improve the treatment outcomes of AML. Histone deacetylase (HDAC) inhibitors have shown potent and specific anticancer stem cell activities in preclinical studies. Chidamide, a novel benzamide-type selectively HDAC inhibitor, has been reported to induce G1 arrest and apoptosis in the relatively mature progenitor population, whereas its effect on primitive LSCs has not been clarified. In this study, we demonstrated that chidamide specifically induces apoptosis in LSC-like cells and primary AML CD34+ cells in a concentration- and time-dependent manner. Our further molecular mechanistic study uncovered that chidamide induces LSCs death by activation of reactive oxygen species (ROS). It compromises the mitochondria membrane potential, modulates antiapoptotic and pro-apoptotic proteins in BCL2 family and activates caspase-3 leading to PARP degradation. Meanwhile, chidamide activates CD40 and modulates its downstream signaling pathways, JNK and NFκB. The results of this study suggest that chidamide may be a novel LSC-targeting agent for AML therapeutics.
Export Options
About this article
Cite this article as:
Yin Li, Kai Chen, Yong Zhou, Yiren Xiao, Manman Deng, Zhiwu Jiang, Wei Ye, Xiangmeng Wang and Xinru Wei, Jie Li, Jiabao Liang, Zhongxin Zheng, Yao Yao, Weiguang Wang, Peng Li and Bing Xu , A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor, Current Cancer Drug Targets 2015; 15 (6) . https://dx.doi.org/10.2174/156800961506150805153230
DOI https://dx.doi.org/10.2174/156800961506150805153230 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
(Review Article) Screening for Disease-Markers and Investigating Drug Effects by Proteome Profiling: Can it Meet Expectations?
Combinatorial Chemistry & High Throughput Screening Protein Microarrays: Technological Aspects, Applications and Intellectual Property
Recent Patents on Biotechnology Severe Hypoglycemia Due to Possible Interaction Between Glibenclamide and Sorafenib in a Patient with Hepatocellular Carcinoma
Current Drug Safety Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies
Current Medicinal Chemistry Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity
Medicinal Chemistry Overview of Ribonucleotide Reductase Inhibitors: An Appealing Target in Anti-Tumour Therapy
Current Medicinal Chemistry Thiopurines in Inflammatory Bowel Disease - The Role of Pharmacogenetics and Therapeutic Drug Monitoring
Current Pharmacogenomics HSP90 Inhibitors: Multi-Targeted Antitumor Effects and Novel Combinatorial Therapeutic Approaches in Cancer Therapy
Current Medicinal Chemistry Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Role of Cytokines in Regulating Feeding Behaviour
Current Drug Targets Podophyllotoxin: Current Perspectives
Current Bioactive Compounds Advancements in Adjuvanticity of Bioactive Inorganic and Organic Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Heat Shock Protein 90 – a Potential Target in the Treatment of Human Acute Myelogenous Leukemia
Current Cancer Drug Targets Effects of Bioactive Compounds from Carrots (Daucus carota L.), Polyacetylenes, Beta-Carotene and Lutein on Human Lymphoid Leukaemia Cells
Anti-Cancer Agents in Medicinal Chemistry Retinoids in Clinical Use
Medicinal Chemistry Anti-Angiogenic and Anti-Inflammatory Effects of Statins: Relevance to Anti-Cancer Therapy
Current Cancer Drug Targets Mitochondrial Permeability Transition as Target of Anticancer Drugs
Current Pharmaceutical Design Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
Current Cancer Drug Targets N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery AG490 Promotes HIF-1α Accumulation by Inhibiting Its Hydroxylation
Current Medicinal Chemistry